PLCO Skin Secures $15 Million Series A Funding to Advance Soft Tissue Repair and Anti-Aging Biomaterials

Recently, PLCO Skin, a South Korean innovator in biomaterials and medical aesthetics technology, announced the completion of a $15 million Series A financing round. The round was jointly invested by a listed South Korean medical aesthetics company and investment institutions from China, Japan, and South Korea, including industrial capital and professional investment firms such as China’s HLC (HighLight Capital), South Korea’s leading medical aesthetics institution Abijou Group, and Japan’s SBI Investment.

The funds raised will be primarily used to: accelerate the Company’s R&D and clinical validation in the fields of soft tissue repair biomaterials and next-generation medical aesthetic anti-aging materials, and promote the industrialization of its products; construct large-scale production lines compliant with GMP standards; and simultaneously advance regulatory market access in core overseas markets, including the United States, Japan, and China, thereby further solidifying the foundation for the Company’s global expansion.

Headquartered in Seoul, South Korea, PLCO Skin was founded by Dr. Baek Wooyeol, a renowned plastic surgeon and Professor of Plastic Surgery at Yonsei University College of Medicine. Leveraging multiple proprietary core technology platforms, the company specializes in developing soft-tissue repair biomaterials and next-generation medical aesthetic anti-aging materials with significant differentiated advantages, serving both high-growth sectors: serious healthcare (soft-tissue reconstruction and repair) and the consumption upgrade in medical aesthetics.

PLCO Skin has obtained Class IV (the highest risk category) medical device certification from South Korea’s Ministry of Food and Drug Safety (MFDS) for some of its core products, and is actively advancing registration and approval processes with overseas regulatory agencies such as the U.S. Food and Drug Administration (FDA), preparing to enter mainstream international markets.

Dr. Baek Wooyeol, Founder and CEO of PLCO Skinstated: “We are deeply honored to have secured support from South Korea’s medical aesthetics industry and international investors with extensive industry experience. Moving forward, PLCO Skin will continue to deepen technological innovation in the fields of soft tissue reconstruction and repair, as well as medical aesthetic anti-aging materials, accelerate global regulatory approvals and clinical adoption, and bring more innovative achievements to clinical practice and the market, thereby benefiting patients and consumers worldwide.”